MedPath

FDA Grants Priority Review for Indivior's SUBLOCADE® Expansion

• The FDA granted Priority Review to Indivior's sNDA for SUBLOCADE®, setting a PDUFA date of February 7, 2025. • The sNDA seeks approval for alternative injection sites (thigh, buttock, back of the arm) for both induction and maintenance. • The submission includes a rapid induction protocol, reducing induction time to one hour after a single transmucosal buprenorphine dose. • If approved, these label updates would significantly enhance patient experience and expand treatment access for opioid use disorder.

Indivior PLC announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation to its Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection. The Prescription Drug User Fee Act (PDUFA) action date is set for February 7, 2025.
SUBLOCADE, a monthly injectable formulation of buprenorphine, is used for treating moderate to severe opioid use disorder (OUD). The PAS aims to broaden treatment options with two proposed label updates: alternative injection sites and a rapid induction protocol.

Alternative Injection Sites

The proposed label expansion includes alternative subcutaneous injection sites in the thigh, buttock, and back of the upper arm for both induction and maintenance. Currently, SUBLOCADE is only approved for subcutaneous abdominal injection.

Rapid Induction Protocol

The PAS also seeks approval for a rapid induction protocol. This protocol reduces the treatment induction time from the current minimum of 7 days on transmucosal buprenorphine (TM BUP) to a single dose of TM BUP with a one-hour observation period to confirm tolerability. Furthermore, it allows for the second 300 mg dose to be administered as early as one week after the initial 300 mg injection, based on patient needs.
Indivior's submission included data demonstrating the efficacy and safety of the new rapid induction protocol and SUBLOCADE's pharmacokinetic profile following injection at alternative sites. The company believes these updates will enhance the patient experience and expand treatment access, particularly for patients with long-term opioid use, including fentanyl.
A Priority Review designation means the FDA aims to take action on the application within 6 months, compared to the standard 10 months. If approved, these changes could lead to significant improvements in OUD treatment with SUBLOCADE.
SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days. It should be used as part of a complete treatment plan that includes counseling and psychosocial support.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Theradaptive's OsteoAdapt SP Spinal Fusion Trial Expands to ALIF and LLIF Procedures

Theradaptive's OsteoAdapt SP clinical trial expands to include anterior lumbar interbody fusion (ALIF) and lateral lumbar interbody fusion (LLIF) procedures, alongside the existing transforaminal interbody fusion (TLIF) approach.
The FDA approved expansion triples the number of investigational sites in the U.S., facilitating broader patient access to the study of this novel therapy for degenerative disc disease.

FDA Accepts Aldeyra's Reproxalap NDA for Dry Eye Disease, Expands AbbVie Partnership

The FDA has accepted for review Aldeyra Therapeutics' resubmitted NDA for reproxalap, a novel drug for treating dry eye disease, with a PDUFA date of April 2, 2025.
Aldeyra and AbbVie have expanded their option agreement, with AbbVie potentially paying Aldeyra $100 million upfront upon exercising its option for reproxalap.

FDA Accepts Dupixent sBLA for Chronic Spontaneous Urticaria Treatment

The FDA has accepted the resubmitted sBLA for Dupixent to treat chronic spontaneous urticaria (CSU) in patients 12 years and older whose condition is not adequately controlled by H1 antihistamines.
The sBLA is supported by data from the LIBERTY-CUPID phase 3 clinical program, which demonstrated significant reductions in itch and urticaria activity with Dupixent.

FDA Accepts Dupixent sBLA for Chronic Spontaneous Urticaria Treatment

The FDA has accepted the resubmitted sBLA for Dupixent to treat chronic spontaneous urticaria (CSU) in patients 12 years and older uncontrolled by antihistamines.
The sBLA is supported by data from the LIBERTY-CUPID phase 3 program, demonstrating significant reductions in itch and urticaria activity.

ResQ Pharma's LipidRescue Receives FDA PDUFA Date for LAST Treatment

ResQ Pharma's LipidRescue Kit has been granted a PDUFA date of June 2, 2025, by the FDA, marking a significant step toward potential approval.
LipidRescue is designed as a drug/device combination to rapidly administer lipid emulsion, counteracting the toxicity of local anesthetics in LAST.

FDA Grants Priority Review to Soleno's DCCR for Prader-Willi Syndrome

The FDA has accepted Soleno Therapeutics' NDA for DCCR, granting Priority Review for treating hyperphagia in Prader-Willi Syndrome (PWS) patients aged four and older.
A PDUFA target action date is set for December 27, 2024, with the FDA planning an advisory committee meeting to discuss DCCR's application.

FDA Grants Priority Review for Setmelanotide sNDA in Young Children with Rare Genetic Obesity

The FDA has accepted Rhythm Pharmaceuticals' sNDA for setmelanotide, seeking approval for children aged 2-6 with obesity due to Bardet-Biedl syndrome or POMC/LEPR deficiency.
The sNDA is supported by Phase 3 trial data showing a 3.04 mean reduction in BMI-Z score and an 18.4% mean reduction in BMI with setmelanotide treatment.

FDA Accepts Vertex's Suzetrigine NDA with Priority Review for Acute Pain

The FDA has accepted Vertex's NDA for suzetrigine, a novel, oral NaV1.8 inhibitor, for treating moderate-to-severe acute pain, potentially the first new class in over 20 years.
Suzetrigine received priority review with a PDUFA target date of January 30, 2025, and has been granted Fast Track and Breakthrough Therapy designations by the FDA.

FDA Accepts Resubmission of NDA for Oral Sulopenem in Uncomplicated UTIs

The FDA has accepted Iterum Therapeutics' resubmitted New Drug Application (NDA) for oral sulopenem for treating uncomplicated urinary tract infections (uUTIs).
The FDA has granted a Prescription Drug User Fee Act (PDUFA) action date of October 25, 2024, for oral sulopenem.

U.S. FDA Grants Priority Review for Elafibranor, a Potential New Treatment for Primary Biliary Cholangitis

The U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of elafibranor, a potential novel second-line treatment for primary biliary cholangitis (PBC), a rare cholestatic liver disease. The European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have also validated the Marketing Authorization Application (MAA) for review. The target FDA PDUFA date is set for June 10, 2024.

Reference News

[1]
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval ... - PR Newswire
prnewswire.com · Oct 7, 2024

Indivior's PAS for SUBLOCADE granted Priority Review by FDA; PDUFA date set for February 7, 2025. PAS seeks label update...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy